PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.55
Negative P/E while Biotechnology median is -4.48. Seth Klarman would scrutinize path to profitability versus peers.
120.38
P/S exceeding 1.5x Biotechnology median of 4.90. Jim Chanos would check for potential multiple compression risks.
1.64
P/B 50-90% of Biotechnology median of 2.65. Mohnish Pabrai would examine if this discount presents opportunity.
-19.55
Negative FCF while Biotechnology median P/FCF is -18.71. Seth Klarman would investigate cash flow improvement potential.
-19.57
Negative operating cash flow while Biotechnology median P/OCF is -18.76. Seth Klarman would investigate operational improvement potential.
1.64
Fair value ratio 50-90% of Biotechnology median of 2.68. Mohnish Pabrai would examine if this gap presents opportunity.
-4.50%
Negative earnings while Biotechnology median yield is -3.77%. Seth Klarman would investigate path to profitability.
-5.12%
Negative FCF while Biotechnology median yield is -3.14%. Seth Klarman would investigate cash flow improvement potential.